Oncologia

Estudo randomizado de fase 2 | Adição de nintedanibe ou placebo à gentacitabina e cisplatina neoadjuvante no câncer de bexiga com invasão muscular localmente avançado.

27 Abr, 2022 | 15:05h

Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial – The Lancet Oncology

 

Comentário no Twitter

In the phase II NEOBLADE trial in 120 pts with locally advanced MIBC, addition of the multitarget RTK TKI nindetanib to neoadjuvant chemotherapy did not significantly improve the pCR rate: 37% versus 32% (OR 1.25, 70% CI 0.84–1.87; P=0.28): https://t.co/m9NXouhOcZ #blcsm

— NatureRevClinOncol (@NatRevClinOncol) April 22, 2022

 

---

Estudo randomizado | Pembrolizumabe vs. quimioterapia para câncer colorretal metastático com alta instabilidade microssatélite ou deficiência no reparo de incompatibilidade (mismatch repair – MMR).

27 Abr, 2022 | 15:03h

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study – The Lancet Oncology (link para o resumo – $ para o texto completo)

Comentário: Overall Survival in KEYNOTE-177: Pembrolizumab vs Chemotherapy in Microsatellite Instability–High or Mismatch Repair–Deficient Metastatic Colorectal Cancer – The ASCO Post

---

M-A | Eficácia clínica dos tratamentos adjuvantes para pacientes com câncer de vias biliares ressecado.

25 Abr, 2022 | 12:37h

Clinical efficacy of adjuvant treatments for patients with resected biliary tract cancer: a systematic review and network meta-analysis – BMJ Open

---

Revisão | Novos tratamentos para linfomas não Hodgkin de células B.

25 Abr, 2022 | 12:36h

Novel treatments in B cell non-Hodgkin’s lymphomas – The BMJ

 

Comentário no Twitter

READ: new State of the Art review on novel treatments in B cell non-Hodgkin’s lymphomas.

Learn about mechanisms of action, efficacy and safety, current therapeutic roles, and future directions in treatment https://t.co/EIri6jDBcv

— The BMJ (@bmj_latest) April 22, 2022

 

---

Atualização de diretriz ASCO | Biomarcadores para quimioterapia e terapia endócrina adjuvante em câncer de mama em estágio inicial.

21 Abr, 2022 | 12:24h

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update – Journal of Clinical Oncology

---

M-A | Associação entre imunoterápicos para o tratamento do câncer e eventos adversos neurológicos.

21 Abr, 2022 | 12:15h

Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis – JAMA Network Open

Comentário convidado: Neurological Toxic Effects Associated With Treatment With Immune Checkpoint Inhibitors—Are We Really Safer Now? – JAMA Network Open

Conteúdos relacionados:

Autoimmune Encephalitis Related to Cancer Treatment With Immune Checkpoint Inhibitors: Systematic Review – Neurology (link para o resumo – $ para o texto completo)

Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system – Therapeutic Advances in Neurologic Disorders

 

Comentário no Twitter

Meta-analysis of 39 RCTs found immune checkpoint inhibitors have lower risk of neurological adverse effects compared to cytotoxic chemotherapy, but higher than placebo, across a range of malignancies. https://t.co/02GhICcu5H

— JAMA Network Open (@JAMANetworkOpen) April 19, 2022

 

---

Estudo randomizado | Sintilimabe vs. placebo em combinação com quimioterapia como tratamento de primeira linha para carcinoma esofágico de células escamosas metastático ou localmente avançado.

21 Abr, 2022 | 12:13h

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial – The BMJ

 

Comentário no Twitter

Compared with placebo, sintilimab in combination with chemo showed significant benefits in overall survival and progression free survival as first line treatment in patients with advanced or metastatic oesophageal squamous cell carcinoma, finds study https://t.co/m8Gn3SBmCu

— The BMJ (@bmj_latest) April 19, 2022

 

---

Desenvolvimento e validação de modelos de aprendizado de máquina (machine learning) para prever metástases nodais ocultas no carcinoma de células escamosas da cavidade oral em estágio inicial.

21 Abr, 2022 | 12:01h

Development and Validation of Machine Learning Models for Predicting Occult Nodal Metastasis in Early-Stage Oral Cavity Squamous Cell Carcinoma – JAMA Network Open

 

Comentário no Twitter

In this diagnostic modeling study, #MachineLearning models built with multi-institutional data showed potential to reduce morbidity from elective neck dissections with similar cancer outcomes in patients with early-stage oral cavity squamous cell carcinoma https://t.co/aRktgc0ms6

— JAMA Network Open (@JAMANetworkOpen) April 13, 2022

 

---

Estudo randomizado | Manutenção da terapia com fuzuloparibe em pacientes com carcinoma ovariano recorrente e sensível a platina.

21 Abr, 2022 | 11:59h

Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)

---

Opinião | Câncer de próstata de baixo grau (escore 6 de Gleason): hora de parar de chamar isso de câncer.

21 Abr, 2022 | 11:44h

Low-Grade Prostate Cancer: Time to Stop Calling It Cancer – Journal of Clinical Oncology

Comentário: Doctors suggest new names for low-grade prostate cancer – Associated Press

---